Mesenchymal Stem Cell in Patients With Acute Severe Respiratory Failure (STELLAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02112500|
Recruitment Status : Unknown
Verified January 2016 by Sang Bum Hong, Asan Medical Center.
Recruitment status was: Recruiting
First Posted : April 14, 2014
Last Update Posted : January 11, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Although the advent of advanced medical support for respiratory failure, the mortality rate of acute severe respiratory failure is still high and the life quality is frequently compromised from pulmonary fibrosis.
The investigators hypothesize that the treatment using mesenchymal stem cell can be beneficial in patients with respiratory failure. The present study is a pilot study evaluating the efficacy and safety of mesenchymal stem cell treatment in patients with respiratory failure.
|Condition or disease||Intervention/treatment||Phase|
|Respiratory Distress Syndrome, Adult||Biological: Mesenchymal Stem Cell||Phase 2|
Although the advent of advanced medical support for respiratory failure, the mortality rate of acute severe respiratory failure is still reported to be more than 40%. The respiratory distress syndrome may develop in all ages resulting in progressive pulmonary fibrosis. A number of survivors from respiratory failure suffer from the sequelas of pulmonary fibrosis.
However, the treatments of respiratory failure are limited to the correction of baseline disease, cardiopulmonary support, and conservative management to minimize the lung injury. There has not been any effective and specific treatment for respirator distress nor medicine to reduce mortality.
There have been reports of mesenchymal stem cell experimental animals with chronic obstructive pulmonary disease, interstitial lung disease, and sepsis. In addition, the mesenchymal stem cell treatment showed beneficial effect in bleomycin endotoxin induced lung injury.
Authors hypothesize that the mesenchymal stem cell treatment in patients with respiratory failure will show efficacy. We would conduct the present pilot study to evaluate the efficacy and safety in patients with respiratory failure and intend to suggest an additional alternative treatment option for those without additional treatment option.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study for the Efficacy and Safety of Mesenchymal Stem Cell in Acute Severe Respiratory Failure.|
|Study Start Date :||February 2014|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2016|
Experimental: Mesenchymal Stem Cell Infusion
Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
Biological: Mesenchymal Stem Cell
Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
Other Name: Lungcellgram
- Oxygen index at 3 days after mesenchymal stem cell infusion [ Time Frame: 3 days after mesenchymal stem cell infusion ]Oxygen index at 3 days after mesenchymal stem cell infusion. Oxygen index is calculated as follows; ((FiO2) x (Mean airway pressure)) / (PaO2)
- Lung mechanics [ Time Frame: at 3, 14, and 28 days after mesenchymal stem cell infusion ]Lung mechanics includes arterial oxygen saturation, tidal volume, minute ventilation, and ratio of PaO2/FiO2.
- Hemodynamic parameters [ Time Frame: at 3, 14, and 28 days after mesenchymal stem cell infusion ]Systolic, diastolic, and mean arterial blood pressure Amount of required vasopressor Heart rate
- Mortality [ Time Frame: at 14 and 28 days after mesenchymal stem cell infusion ]Death from any cause at 14 and 28 days after mesenchymal stem cell infusion
- Plasma cytokines [ Time Frame: at 3, 14, and 28 days after mesenchymal stem cell infusion ]Interleukin (IL)-1, IL-6, IL-8, and IL-10
- Markers for inflammation and infection [ Time Frame: at 3, 14, and 28 days after mesenchymal stem cell infusion ]Lactate, DIC score, SOFA score, C-reactive protein, and procalcitonin
- Ventilator weaning parameters [ Time Frame: at 3, 14, and 28 days after mesenchymal stem cell infusion ]Failure of ventilator weaning, weaning time, ventilation time
- ICU and hospital stay [ Time Frame: at 28 days after mesenchymal stem cell infusion ]Total duration of ICU stay and hospital stay
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||20 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Ventilator care from respiratory failure
- Ventilator care for 7 or more days
at least one of the followings
- PaO2/FiO2 = 200 or less when PEEP 5 cmH2O or more.
- PaCO2 = 50 mmHg or more when plateau pressure of 30 cmH2O or more.
- pH = 7.25 or less when plateau pressure of 30 cmH2O or more.
- No other treatment option except for lung transplantation and not candidate for recipient (organ failure, comorbid infection, economy,...)
- Ventilatory care with weaning failure 3 times or more
Ventilator care requiring 7 days or more from the first self respiration to weaning of ventilator.
- PEEP, positive endexpiratory pressure
- Severe aplastic anemia
- Malignant hematologic disorder or history of stem cell treatment.
- Currently uncontrolled malignancy or history of solid cancer within 2 years
- HIV Infection
- Expected life < 3 months from other cause than the respiratory failure
- Pregnancy or breast feeding
- Expected hypersensitivity for study drug
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02112500
|Contact: Sang Bum Hong, MDemail@example.com|
|Contact: Dong Hyun Lee, MDfirstname.lastname@example.org|
|Korea, Republic of|
|Asan Medical Center||Recruiting|
|Seoul, Korea, Republic of, 138-736|
|Contact: Sang Bum Hong, MD +82-10-6824-9767 email@example.com|
|Principal Investigator: Sang Bum Hong, MD|
|Principal Investigator:||Sang Bum Hong, M.D.||Asan Medical Center|
|Responsible Party:||Sang Bum Hong, MD, Professor of Ulsan University College of Medicine, Asan Medical Center|
|Other Study ID Numbers:||
|First Posted:||April 14, 2014 Key Record Dates|
|Last Update Posted:||January 11, 2016|
|Last Verified:||January 2016|
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Respiratory Tract Diseases
Infant, Premature, Diseases
Infant, Newborn, Diseases